C3 and COVID-19: Nonetheless, the C3 inhibitor AMY-101 was initially used in two case series to treat four COVID-19 patients with acute respiratory distress syndrome, all of whom eventually recovered (Mastaglio et al., 2020; Mastellos et al., 2020).